Holen Sie sich die Stockscreener-App
0.497
2.37%
0.0115
Handel nachbörslich:
.51
0.013
+2.62%
Azitra Inc Aktie (AZTR) Neueste Nachrichten
Azitra to Present at BIO-Europe 2024 - BioSpace
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com
Azitra Joins 2024 Maxim Healthcare Virtual Summit - FinancialNews.co.uk
Netherton Syndrome Treatment Industry is Expected to Reach $8 Billion by 2034 -Lifemax Laboratories, Azitra, Inc, Sixera – IndiaPolitics.com - IndiaPolitics.com
Azitra stock plunges to 52-week low, hits $0.49 By Investing.com - Investing.com South Africa
Azitra stock plunges to 52-week low, hits $0.49 - Investing.com
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia
Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India
AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan
Mexico's inflation undershoots forecasts ahead of rate decision - Investing.com
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire
AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle
FDA fast tracks Azitra's new dermatology treatment - Investing.com
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan
Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Azitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8% - Defense World
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update - Defense World
Azitra Inc’s latest rating changes from various analysts - Knox Daily
A significant driver of top-line growth: Azitra Inc (AZTR) - SETE News
Financial Metrics Exploration: Understanding Azitra Inc (AZTR) Through Ratios - The Dwinnex
Do investors need to be concerned about Azitra Inc (AZTR)? - US Post News
Azitra doses first subject in Phase Ib Netherton syndrome treatment trial - Yahoo Finance
Azitra begins phase 1b trial for Netherton syndrome treatment - Investing.com
Views of Wall Street’s Leading Experts on Azitra Inc - SETE News
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Trading Day Triumph: Azitra Inc (AZTR) Ends at 0.71, a -5.08 Surge/Plunge - The Dwinnex
Azitra Inc [AZTR] stock for 10,034 USD was bought by Staskey Norm - Knox Daily
FDA clears Azitra's Phase 1/2 trial for skin rash treatment - Investing.com
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Marketscreener.com
A Look at Azitra Inc (AZTR) Shares in the Recent Past Indicates Growth - SETE News
Investing in Azitra Inc (AZTR) Is Getting More Attractive - Knox Daily
Azitra Inc Inc. (AZTR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Understanding AZTR stock ratios for better investment decisions - US Post News
Ratio Revelations: Azitra Inc (AZTR)’s Financial Metrics in the Spotlight - The Dwinnex
Azitra screens first subject in Phase Ib trial of ATR-12 for Netherton syndrome - Clinical Trials Arena
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra, Inc. Announces First Patient Screened and Scheduled to Enroll in Phase 1B Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra (NYSEAMERICAN:AZTR) Issues Earnings Results - Defense World
Stock Performance Spotlight: Azitra Inc (AZTR) Ends the Day at 0.70, Up by 2.94 - The Dwinnex
Azitra Inc’s Banking’s 100-Day Moving Average at 4.5289: Will the Stock Break Through? - The InvestChronicle
Get in on Azitra Inc’s (AZTR) buy-in window today! - SETE News
Checking in on Azitra Inc (AZTR) after recent insiders movement - Knox Daily
why Azitra Inc [AZTR] is a Good Choice for Investors After New Price Target of $3.50 - The DBT News
Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates - Marketscreener.com
5.11%
0.50%
Kapitalisierung:
|
Volumen (24h):